

Please check your submission one more time.

Then scroll all the way down to the bottom of this page to submit your abstract.

After you review your submission, scroll all the way down to the bottom of this page to submit your abstract. Please note that if any areas are incomplete, you will be prompted to go back and complete before submitting your abstract. To make updates, select any step from the tool bar menu and edit accordingly. Be sure to save your changed before moving on.

Expenditure on Medicines for the Treatment of Multiple Myeloma in Catalonia for 2021

Saborit-Canals G¹, Lizano Gispert E¹, Garrido Alejos G², Gay D¹, Vallano Ferraz A¹, Roig M¹

¹CatSalut, Barcelona, Spain, ²Institut Català de la Salut, Barcelona, Spain

OBJECTIVES: To analyze the annual expenditure in 2021 of medicines for the treatment of multiple myeloma (MM) in the public health system hospitals of Catalonia.

METHODS: A retrospective cohort study of patients treated with hospital outpatient drugs (HOD) for MM in Catalonia in 2021 was carried out. From the Registry of Patients and Treatments, a clinical-practice database, information on patient demographics and pharmacological treatment was collected about patients treated for MM with Bortezomib, Carfilzomib, Daratumumab, Lenalidomide or Pomalidomide. Treatments cost was analyzed based on billing data from the Catalan Health Service.

RESULTS: Pharmacological treatments for MM were prescribed to 1,489 patients (mean [SD] age 70.3 [11.0] years, 50% women), 3.7% of the all cancer patients and 0.6% of those receiving HOD. The overall 2021 expenditure on MM was €56.8 million, 13.0% of the expenditure on cancer drugs and 4.5% on HOD. Annual cost per patient was €38,117. Highest expenditure and largest number of patients was in second line therapy with €16.3 million (29% overall) for 493 (33% overall) patients. However, with an average of €81,829, first line treatments for non-eligible patients for hematopoietic stem cell transplantation had the highest cost/patient. Lenalidomide was the drug prescribed to most patients (N=1,093; 73% overall) and with the highest expenditure (€30.4M; 54% overall). Daratumumab (N=418; 28%; cost €14.8M; 26%) had the highest cost/patient, with an average of €35,348 for all lines.

CONCLUSIONS: The investment of the Catalan public health system in the pharmacological treatment of MM represents a significant proportion of the total expenditure in HOD, much higher and not correlated with the proportion of patients. Moreover, almost 80% of this expenditure is attributable exclusively to two of the analyzed drugs: Lenalidomide and Daratumumab. Further analysis about combination of drugs and health-related outcomes are necessary to evaluate the current efficiency of MM treatments.

Abstract ID#:

121167

Submitter's E-mail Address:

guillem.saborit@catsalut.cat

Program Selection:

Research

Participation:

We intend to present virtually (at this time)

Preferred Presentation Format:

Poster

Research Study Approach:

Research

Main Topic/Taxonomy:

Economic Evaluation

Subtopics:

Economic Evaluation: Cost/Cost of Illness/Resource Use Studies

Health Policy & Regulatory: Public Spending & National Health Expenditures

Primary Specific Diseases & Cond./Specialized Treatment Areas:

SDC: Oncology

Additional Diseases & Conditions/Specialized Treatment Areas:

STA: Drugs

ISPOR Presentations Database:

Undecided

Guarantor:

Guillem Saborit-Canals

First author*Presenting Author*

Guillem Saborit-Canals, MSc

CatSalut

Travessera de les Corts 131-159

Barcelona, 08028

Spain

Phone Number: 934038817

Email Address: guillem.saborit@catsalut.cat

* Membership Number 3221732

Second author

Enric Lizano Gispert, PhD

CatSalut

Travessera de les Corts 131-159

Barcelona, 08028

Spain

Phone Number: 934038817

Email Address: enric.lizano@catsalut.cat

Third author

Gemma Garrido Alejos, PharmD

Institut Català de la Salut

Barcelona Spain

Email Address: ggarrido@gencat.cat

* Membership Number 3221678

Fourth author

Daniel Gay, MSc

CatSalut

Travessera de les Corts 131-159

Barcelona, 08028

Spain

Phone Number: 934038817

Email Address: dgayp@catsalut.cat

Fifth author

Antoni Vallano Ferraz, MD, PhD
CatSalut
Travessera de les Corts 131-159
Barcelona, 08028
Spain
Phone Number: 934038817
Email Address: avallano@catsalut.cat

Sixth author

Marta Roig, MSc
CatSalut
Travessera de les Corts 131-159
Barcelona, 08028
Spain
Phone Number: 934038817
Email Address: maroig@catsalut.cat

FINAL STEPS

Enter your name (or the name of the lead author) in the certification statement below. - *(Required)*

I, , affirm that this abstract conforms to all the abstract policies and procedures as stated in the Call for Abstracts. I certify that the authors named are familiar with the presented material, agree with the results as stated (original research), and have specifically consented to be included as authors. I certify, represent, and warrant that I have the right to publish this abstract as submitted and agree to indemnify ISPOR from any claims arising from this material, and assign copyright of this abstract to ISPOR. (This abstract will not be accepted unless certified by the submitting author.)

Click to print this page now.

CONCLUDE SUBMISSION